Brainstorm Cell

BCLI NASDAQ
3.770
-0.120
-3.08%
Closed 16:00 05/20 EDT
Open
3.870
Prev Close
3.890
High
3.870
Low
3.740
Volume
47.08K
Avg Vol (3M)
61.17K
52 Week High
5.35
52 Week Low
2.920
% Turnover
0.22%
Market Cap
81.82M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Brainstorm Cell BCLI stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
MORE >

Recently

Name
Price
%Change